MTTP
Microsomal triglyceride transfer protein large subunit
As of the edition of 20 October 2026, MTTP (microsomal triglyceride transfer protein large subunit, UniProt P55157) has 5 drugs tested at it and 6 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P55157
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 2
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Hormones
- Registered trials of its drugs
- 28
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lomitapide | Marketed | Phase 3 | Ends 2029 |
| SLX-4090 | Stopped | Phase 2 | none listed |
| Implitapide | Stopped | Phase 2 | none listed |
| Usistapide | Went quiet | Phase 2 | none listed |
| Granotapide | Went quiet | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Undetermined | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Chiesi Farmaceutici | Route B |
| Johnson & Johnson | Route A |
| Akros Pharma | Route A |
The other 3 companies at MTTP
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at MTTP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.